Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217291 | 0.88 | LPL (0.42) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31217403 | 0.88 | FFAR1 (0.36) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31212564 | 0.85 | LPL (0.40) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31217264 | 0.84 | LPL (0.44) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31217222 | 0.82 | FFAR1 (0.38) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31217161 | 0.82 | AAK1 (0.39) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31217318 | 0.82 | LPL (0.48) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31217371 | 0.82 | LPL (0.48) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31217322 | 0.81 | LPL (0.37) | LPLLIPGFFAR1DGAT1GSK3A | |
| SCHEMBL31217373 | 0.81 | LPL (0.38) | LPLLIPGFFAR1DGAT1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | LPL 3407/4885LIPG 3149/4885FFAR1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.